KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Change in Inventory (2016 - 2025)

Abbott Laboratories' Change in Inventory history spans 17 years, with the latest figure at -$234.0 million for Q4 2025.

  • For Q4 2025, Change in Inventory changed 0.43% year-over-year to -$234.0 million; the TTM value through Dec 2025 reached -$195.0 million, down 436.21%, while the annual FY2025 figure was -$195.0 million, 436.21% down from the prior year.
  • Change in Inventory for Q4 2025 was -$234.0 million at Abbott Laboratories, down from -$213.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $554.0 million in Q1 2022 and bottomed at -$295.0 million in Q4 2023.
  • The 5-year median for Change in Inventory is $54.0 million (2021), against an average of $98.2 million.
  • The largest annual shift saw Change in Inventory soared 9420.0% in 2022 before it crashed 256.08% in 2023.
  • A 5-year view of Change in Inventory shows it stood at -$15.0 million in 2021, then surged by 1360.0% to $189.0 million in 2022, then plummeted by 256.08% to -$295.0 million in 2023, then rose by 20.34% to -$235.0 million in 2024, then rose by 0.43% to -$234.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Change in Inventory are -$234.0 million (Q4 2025), -$213.0 million (Q3 2025), and -$3.0 million (Q2 2025).